Jaimee Sharp Cancelled Ohio Clinical Trial After Shortfall
A fundraising effort for an Ohio-based cancer trial fell £66,000 short of its £320,000 target.
Updated on Oct. 9, 2026 in Cancer
Jaimee Sharp, a 28-year-old with an incurable brain tumour, has cancelled her participation in an Ohio-based clinical trial. The decision followed a fundraising campaign that raised £254,519, leaving the effort £66,000 short of the required £320,000 goal.
Why it matters
The two-year clinical trial program was deemed financially unviable after the fundraising target was not met within the required timeframe. Sharp is now pivoting to private hyperthermia treatment to be used alongside chemotherapy.
The fundraising campaign concluded with £254,519, falling £66,000 short of the £320,000 target required for the two-year U.S. program. This figure represents the total capital available to cover treatment and associated care costs.
The players
Jaimee Sharp
She is a 28-year-old patient currently managing an incurable brain tumour diagnosis.
Teddy
He is the five-year-old son of Jaimee Sharp.
NHS
The National Health Service is the publicly funded healthcare system in the United Kingdom.
The details
Hyperthermia treatment functions by damaging cancer cells, which researchers believe increases their vulnerability to chemotherapy. While this method is not routinely available on the NHS, Sharp plans to utilize the remaining funds to cover these private care costs for herself and her five-year-old son, Teddy.
Timeline
October 8, 2026: Announcement of the trial cancellation.
Health Landscape
The cancellation of the TarGet-D clinical trial highlights the significant financial hurdles patients face when attempting to access experimental international treatments. This situation underscores the limited availability of specialized therapies like hyperthermia within standard public healthcare systems.
Patients seeking experimental treatments may face significant financial risks if fundraising targets are not met in time. Sharp's experience emphasizes the necessity of navigating private care options when standard healthcare pathways are unavailable.
The takeaway
Patients considering international clinical trials should account for potential funding gaps when planning long-term treatment strategies. This case demonstrates the critical importance of evaluating both public and private medical alternatives when a primary care pathway becomes financially unviable.
Further reading
Find more information on the evolving landscape of Cancer research and treatments.
